Hepatitis B is a serious global public health problem; more than 350 million people have lifelong infections. Chronically infected people are at high risk of death from cirrhosis of the liver and liver cancer, which both kill about 1 million people each year. Current antiviral therapies include lamivudine and alpha-interferon which also suppress viral replication by attacking the virus itself, but the identification of the action of this protein offers new therapeutic opportunities by targeting the human proteins that help the virus to replicate.
Citation: Ng LFP, Chan M, Chan SH, Cheng PCP, Leung EHC, et al. (2005) Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med 2(7): e163.
CONTACT:
Professor Ee Chee Ren
Genome Institute of Singapore
60 Biopolis Street
Genome, #02-01
Singapore, Singapore 138672
65-6478-8138
65-6478-9052 (fax)
renec@gis.a-star.edu.sg
PLEASE MENTION PLoS Medicine ( www.plosmedicine.org ) AS THE SOURCE FOR THESE ARTICLES. THANK YOU. All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
PLOS Medicine